Ovid Therapeutics Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $42.3M | $44.2M |
| Jun 2017 | — | $100.9M | $106.1M |
| Sep 2017 | — | $93.0M | $96.0M |
| Dec 2017 | — | $83.4M | $87.1M |
| Mar 2018 | — | $72.1M | $29.2M |
| Jun 2018 | — | $61.1M | $22.5M |
| Sep 2018 | — | $50.0M | $30.5M |
| Dec 2018 | — | $38.8M | $36.5M |
| Mar 2019 | — | $57.2M | $54.6M |
| Jun 2019 | — | $45.4M | $47.4M |
| Sep 2019 | — | $30.0M | $37.9M |
| Dec 2019 | — | $70.0M | $41.9M |
| Mar 2020 | — | $51.4M | $27.3M |
| Jun 2020 | — | $30.5M | $41.3M |
| Sep 2020 | — | $63.6M | $86.9M |
| Dec 2020 | — | $43.6M | $72.0M |
| Mar 2021 | — | $221.1M | $233.1M |
| Jun 2021 | — | $206.7M | $212.2M |
| Sep 2021 | — | $197.0M | $201.8M |
| Dec 2021 | — | $179.7M | $187.8M |
| Mar 2022 | — | $165.0M | $166.7M |
| Jun 2022 | — | $152.1M | $72.8M |
| Sep 2022 | — | $142.1M | $58.3M |
| Dec 2022 | — | $132.3M | $44.9M |
| Mar 2023 | — | $120.9M | $63.1M |
| Jun 2023 | — | $110.7M | $71.6M |
| Sep 2023 | — | $101.3M | $57.4M |
| Dec 2023 | — | $87.8M | $27.0M |
| Mar 2024 | — | $78.3M | $30.8M |
| Jun 2024 | — | $88.9M | $29.7M |
| Sep 2024 | — | $76.3M | $15.0M |
| Dec 2024 | — | $68.2M | $26.3M |
| Mar 2025 | — | $59.3M | $21.1M |
| Jun 2025 | — | $55.8M | $28.4M |
| Sep 2025 | — | $44.7M | $20.6M |
| Dec 2025 | — | $130.7M | $13.2M |
| Mar 2026 | — | $198.3M | $94.1M |
| Jun 2026 | — | $209.9M | $11.3M |